Topic Review
Tumor Microenvironment with Nanoparticle-Based Therapies
Therapies mobilizing host immunity against cancer cells have profoundly improved prognosis of cancer patients. However, efficacy of immunotherapies depends on local immune conditions. The “cold” tumor, which is characterized by lacking inflamed T cells, is insensitive to immunotherapy. Current strategies of improving the “cold” tumor microenvironment are far from satisfying. Nanoparticle-based therapies provide novel inspiration in firing up the tumor microenvironment.
  • 565
  • 08 Oct 2021
Topic Review
Alcohol and Cancer
Approximately 4% of cases of cancer worldwide are caused by alcohol consumption. Drinking alcohol increases the risk of several cancer types, including cancers of the upper aerodigestive tract, liver, colorectum, and breast.
  • 565
  • 25 Oct 2021
Topic Review
Targeted Strategies for Degradation of Key Transmembrane Proteins in Cancer
Targeted protein degradation is an attractive technology for cancer treatment due to its ability to overcome the unpredictability of the small molecule inhibitors that cause resistance mutations. Various targeted protein degradation strategies have been developed based on the ubiquitin–proteasome system in the cytoplasm or the autophagy–lysosomal system during endocytosis. Here describe technologies for the targeted inhibition and targeted degradation of the epidermal growth factor receptor (EGFR), one of the major transmembrane proteins responsible for the onset and progression of many types of cancer.
  • 565
  • 21 Sep 2023
Topic Review
Current Treatment of Glioblastoma
Glioblastoma (GBM) is the most common form of primary malignant brain tumor with a devastatingly poor prognosis. The disease does not discriminate, affecting adults and children of both sexes, and has an average overall survival of 12–15 months, despite advances in diagnosis and rigorous treatment with chemotherapy, radiation therapy, and surgical resection. In addition, most survivors will eventually experience tumor recurrence that only imparts survival of a few months. GBM is highly heterogenous, invasive, vascularized, and almost always inaccessible for treatment. Based on all these outstanding obstacles, there have been tremendous efforts to develop alternative treatment options that allow for more efficient targeting of the tumor including small molecule drugs and immunotherapies. A number of other strategies in development include therapies based on nanoparticles, light, extracellular vesicles, and micro-RNA, and vessel co-option. Advances in these potential approaches shed a promising outlook on the future of GBM treatment.
  • 564
  • 22 Sep 2021
Topic Review
Mast Cell Activation
Mast cell activation (MCA) may occur in different physiologic and pathologic conditions. Clinical symptoms resulting from MCA can be observed not only in the setting of allergic diseases, but even in the context of MC neoplasms. If MCA symptoms are severe and recurrent, the possibility of mast cell activation syndrome (MCAS) should be considered.
  • 564
  • 12 Oct 2021
Topic Review
Precision Medicine for Colorectal Cancer
In the field of colorectal cancer (CRC) treatment, diagnostic modalities and chemotherapy regimens have progressed remarkably in the last two decades. However, it is still difficult to identify minimal residual disease (MRD) necessary for early detection of recurrence/relapse of tumors and to select and provide appropriate drugs timely before a tumor becomes multi-drug-resistant and more aggressive.
  • 564
  • 28 Sep 2021
Topic Review
Cancer Stem Cells in TNBC
Triple negative breast cancer (TNBC) remains an aggressive disease due to the lack of targeted therapies and low rate of response to chemotherapy that is currently the main treatment modality for TNBC. Breast cancer stem cells (BCSCs) are a small subpopulation of breast tumors and recognized as drivers of tumorigenesis. TNBC tumors are characterized as being enriched for BCSCs. Growing evidence has shown that breast cancer stem cells are associated with tumor initiation and metastasis and may play a critical role in chemoresistance. Multiple targets against breast cancer stem cells are now under investigation. Recent advances in the role of breast cancer stem cells in triple negative breast cancer and the identification of cancer stem cell biomarkers have paved the way for the development of new targeted therapies.
  • 564
  • 17 Dec 2021
Topic Review
A Theranostic Approach in Selective Internal Radiation Therapy
Selective internal radiation therapy (SIRT) is one of the treatment options for liver tumors. Microspheres labelled with a therapeutic radionuclide (90Y or 166Ho) are injected into the liver artery feeding the tumor(s), usually achieving a high tumor absorbed dose and a high tumor control rate. This treatment adopts a theranostic approach with a mandatory simulation phase, using a surrogate to radioactive microspheres (99mTc-macroaggregated albumin, MAA) or a scout dose of 166Ho microspheres, imaged by single photon emission computed tomography (SPECT)/CT.
  • 564
  • 03 Jan 2023
Topic Review
Microneedles in Cancer Therapy and Diagnosis
The tumor is an uncontrolled growth of tissue that can be localized (benign) or possesses the capability of metastasis (malignant). The conventional methods of tumor diagnosis, such as acupuncture, endoscopy, and histopathology, and treatment methods, such as injections, chemotherapy, surgery, and radiotherapy, are invasive, expensive, and pose severe safety and management issues for the patients. Microneedle technology is minimally invasive, self-administrable, bypasses the first-pass effect, effectively delivers chemotherapeutics and drugs at low doses, and provides drug diffusion into the tumor areas, thus, overcoming the drawbacks of conventional delivery systems.
  • 564
  • 12 Jan 2023
Topic Review
Brain-Gut Axis
The brain-gut axis represents a complex bi-directional system comprising multiple interconnections between the neuroendocrine pathways, the autonomous nervous system and the gastrointestinal tract. Inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, is a chronic, relapsing-remitting inflammatory disorder of the gastrointestinal tract with a multifactorial etiology. 
  • 563
  • 25 Feb 2021
Topic Review
FGF/FGFR Signaling in Hepatocellular Carcinoma
As the most common primary liver cancer, HCC is a tricky cancer resistant to systemic therapies. The fibroblast growth factor family and its receptors are gaining more and more attention in various cancers. Noticing an explosion in the number of studies about aberrant FGF/FGFR signaling in HCC being studied, we were encouraged to summarize them.
  • 563
  • 25 May 2021
Topic Review
Deubiquitinating Enzymes in Hematopoiesis
Hematopoietic stem cells (HSCs) are responsible for the production of blood cells throughout the human lifespan. Single HSCs can give rise to at least eight distinct blood-cell lineages. Together, hematopoiesis, erythropoiesis, and angiogenesis coordinate several biological processes, i.e., cellular interactions during development and proliferation, guided migration, lineage programming, and reprogramming by transcription factors. Any dysregulation of these processes can result in hematological disorders and/or malignancies. Several studies of the molecular mechanisms governing HSC maintenance have demonstrated that protein regulation by the ubiquitin proteasomal pathway is crucial for normal HSC function. Recent studies have shown that reversal of ubiquitination by deubiquitinating enzymes (DUBs) plays an equally important role in hematopoiesis; however, information regarding the biological function of DUBs is limited.
  • 563
  • 23 Jun 2021
Topic Review
Mutant p53 Functions
Active p53 is a homotetramer of four identical chains of 393 amino acids. Each monomer presents a modular structure divided into different domains: an acidic disorderedN-terminal region, comprising the transactivation domain (TAD) and the proline-rich region (PRR); a central core sequence-specific DNA-binding domain (DBD); aC-terminal region, encompassing an oligomerization domain (OD) and a disordered regulatory domain (CRD)().
  • 563
  • 29 Jul 2021
Topic Review
ICIs in Ovarian Cancer
Ovarian cancer (OC) represents the fifth leading cause of cancer-related deaths among women. In the advanced disease setting, OC recurrence after chemotherapy is over 70% in the first 2 years, with few therapeutic options. Immunotherapy with the immune checkpoint inhibitors (ICIs) showed high efficacy and changed the therapeutic scenario of many tumors in the last 10 years.
  • 563
  • 13 Sep 2021
Topic Review
Genomic Instability in Multiple Myeloma
Multiple Myeloma (MM) is a genetically complex and heterogeneous hematological cancer that remains incurable despite the introduction of novel therapies in the clinic. The surprising finding that MM cells present rampant genomic instability has ignited concerted efforts to understand its origin and exploit it for therapeutic purposes.
  • 563
  • 11 Jan 2022
Topic Review
Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
The presence of “hypoxic” tissue (with O2 levels of <0.1 mmHg) in solid tumours, resulting in quiescent tumour cells distant from blood vessels, but capable of being reactivated by reoxygenation following conventional therapy (radiation or drugs), have long been known as a limitation to successful cancer chemotherapy. This has resulted in a sustained effort to develop nitroaromatic “hypoxia-activated prodrugs” designed to undergo enzyme-based nitro group reduction selectively in these hypoxic regions, to generate active drugs. Such nitro-based prodrugs can be classified into two major groups; those activated either by electron redistribution or by fragmentation following nitro group reduction, relying on the extraordinary difference in electron demand between an aromatic nitro group and its reduction products. 
  • 563
  • 22 Apr 2022
Topic Review
Organoids in Pediatric Brain Tumor Precision Medicine
Malignant brain neoplasms are a heterogeneous group of tumors, including glioma, ependymoma, embryonal tumors, and many other (rare) entities and subentities, affecting patients from birth to adulthood. Organoids emerged as three-dimensional (3D) cell culture systems for modeling healthy and diseased tissues. These organoids potentially model development, diseases, and drug responses [13]. They are self-organizing three-dimensional structures that closely mimic an organ or tissue at a morphological, cellular, and functional level.
  • 563
  • 19 Dec 2022
Topic Review
Extracellular Vesicles in Malignant Melanoma
Different types of cells, such as endothelial cells, tumor-associated fibroblasts, pericytes, and immune cells, release extracellular vesicles (EVs) in the tumor microenvironment. The components of EVs include proteins, DNA, RNA, and microRNA. One of the most important functions of EVs is the transfer of aforementioned bioactive molecules, which in cancer cells may affect tumor growth, progression, angiogenesis, and metastatic spread. Furthermore, EVs affect the presentation of antigens to immune cells via the transfer of nucleic acids, peptides, and proteins to recipient cells. 
  • 562
  • 28 Oct 2021
Topic Review
Immunosuppressive Tumor Microenvironment
Several cellular elements of the bone marrow (BM) microenvironment in multiple myeloma (MM) patients contribute to the immune evasion, proliferation, and drug resistance of MM cells, including myeloid-derived suppressor cells (MDSCs), tumor-associated M2-like, “alternatively activated” macrophages, CD38+ regulatory B-cells (Bregs), and regulatory T-cells (Tregs). 
  • 561
  • 23 Jun 2021
Topic Review
Microvascular Invasion in Hepatocellular Carcinoma
Microvascular invasion (MVI) is regarded as a sign of early metastasis in liver cancer and can be only diagnosed by a histopathology exam in the resected specimen. Preoperative prediction of MVI status may exert an effect on patient treatment management, for instance, to expand the resection margin.
  • 561
  • 16 Dec 2021
  • Page
  • of
  • 128
ScholarVision Creations